Results 51 to 60 of about 56,924 (160)

Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

EMBO Molecular Medicine, 2018
Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug ...
Ileabett M Echevarría‐Vargas, Patricia I Reyes‐Uribe, Adam N Guterres, Xiangfan Yin, Andrew V Kossenkov, Qin Liu, Gao Zhang, Clemens Krepler, Chaoran Cheng, Zhi Wei, Rajasekharan Somasundaram, Giorgos Karakousis, Wei Xu, Jennifer JD Morrissette, Yiling Lu, Gordon B Mills, Ryan J Sullivan, Miao Benchun, Dennie T Frederick, Genevieve Boland, Keith T Flaherty, Ashani T Weeraratna, Meenhard Herlyn, Ravi Amaravadi, Lynn M Schuchter, Christin E Burd, Andrew E Aplin, Xiaowei Xu, Jessie Villanueva   +28 more
doaj   +1 more source

PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer

Journal of Experimental & Clinical Cancer Research, 2019
s Background Overexpressed PES1 promotes carcinogenesis in various types of malignant tumors. However, the biological role and clinical significance of PES1 in pancreatic cancer are still unexplored.
Xin Jin, Rui Fang, Ping Fan, Lipeng Zeng, Bin Zhang, Xiaoming Lu, Tao Liu   +6 more
doaj   +1 more source

Relevance of BET Family Proteins in SARS-CoV-2 Infection

Biomolecules, 2021
The recent pandemic we are experiencing caused by the coronavirus disease 2019 (COVID-19) has put the world’s population on the rack, with more than 191 million cases and more than 4.1 million deaths confirmed to date.
Nieves Lara-Ureña, Mario García-Domínguez   +1 more
doaj   +1 more source

Mapping genetic interactions in cancer: a road to rational combination therapies. [PDF]

, 2019
The discovery of synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) inhibitors and BRCA genes, which are involved in homologous recombination, led to the approval of PARP inhibition as a monotherapy for patients with BRCA1/2 ...
Krogan, Nevan J, Tutuncuoglu, Beril
core  

The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]

, 2017
Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core   +1 more source

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer

Cell Reports, 2018
Summary: BRD4 plays a major role in the transcription networks orchestrated by androgen receptor (AR) in castration-resistant prostate cancer (CRPC). Several BET inhibitors (BETi) that displace BRD4 from chromatin are being evaluated in clinical trials ...
Aishwarya Pawar, Paradesi Naidu Gollavilli, Shaomeng Wang, Irfan A. Asangani   +3 more
doaj   +1 more source

Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. [PDF]

, 2019
Solid tumours are infiltrated by effector T cells with the potential to control or reject them, as well as by regulatory T (Treg) cells that restrict the function of effector T cells and thereby promote tumour growth1.
Cadilha, Bruno L, Carrizosa, Esteban, Di Pilato, Mauro, Kim, Edward Y, Ligorio, Matteo, Mani, Vinidhra, Marangoni, Francesco, Medoff, Benjamin D, Mempel, Thorsten R, Misale, Sandra, Nasrallah, Mazen N, Prüßmann, Jasper N, Seruggia, Davide, Usmani, Shariq M, Villani, Alexandra-Chloe, Warner, Ross D, Zappulli, Valentina   +16 more
core   +2 more sources

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas [PDF]

, 2018
FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K-mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells.
Aplin, Andrew E., Berger, Adam C., Bollag, Gideon, Davies, Michael A., Goldberg, Allison F., Hartsough, Edward J., Knudsen, Karen E., Kugel, Curtis H., Purwin, Timothy J., Schiewer, Matthew J., Vido, Michael J.   +10 more
core   +1 more source

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. [PDF]

, 2018
We have shown that antagomiR inhibition of miRNA miR-21 and miR-196b activity is sufficient to ablate MLL-AF9 leukemia stem cells (LSC) in vivo. Here, we used an shRNA screening approach to mimic miRNA activity on experimentally verified miR-196b targets
Aronow, Bruce J., Doench, John G., Grimes, H. Leighton, Lal, Ashish, Lieberman, Judy, McGlinn, Edwina, Meyer, Sara E., Morris, Patrick J., Muench, David E., Newkold, Tess J., O\u27Brien, Eric, Orr, Emily, Perentesis, John P., Rogers, Andrew M., Salomonis, Nathan, Thomas, Craig J.   +15 more
core   +2 more sources

BRD4 short isoform interacts with RRP1B, SIPA1 and components of the LINC complex at the inner face of the nuclear membrane.

PLoS ONE, 2013
Recent studies suggest that BET inhibitors are effective anti-cancer therapeutics. Here we show that BET inhibitors are effective against murine primary mammary tumors, but not pulmonary metastases.
Jude Alsarraj, Farhoud Faraji, Thomas R Geiger, Katherine R Mattaini, Mia Williams, Josephine Wu, Ngoc-Han Ha, Tyler Merlino, Renard C Walker, Allen D Bosley, Zhen Xiao, Thorkell Andresson, Dominic Esposito, Nicholas Smithers, Dave Lugo, Rab Prinjha, Anup Day, Nigel P S Crawford, Keiko Ozato, Kevin Gardner, Kent W Hunter   +20 more
doaj   +1 more source